Harmony Biosciences (HRMY) Competitors $34.40 -0.78 (-2.22%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$34.38 -0.02 (-0.04%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HRMY vs. BPMC, LEGN, ROIV, RGC, ELAN, RVMD, GRFS, TGTX, NUVL, and CRSPShould you be buying Harmony Biosciences stock or one of its competitors? The main competitors of Harmony Biosciences include Blueprint Medicines (BPMC), Legend Biotech (LEGN), Roivant Sciences (ROIV), Regencell Bioscience (RGC), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry. Harmony Biosciences vs. Its Competitors Blueprint Medicines Legend Biotech Roivant Sciences Regencell Bioscience Elanco Animal Health Revolution Medicines Grifols TG Therapeutics Nuvalent CRISPR Therapeutics Blueprint Medicines (NASDAQ:BPMC) and Harmony Biosciences (NASDAQ:HRMY) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends. Do institutionals and insiders have more ownership in BPMC or HRMY? 86.2% of Harmony Biosciences shares are held by institutional investors. 4.2% of Blueprint Medicines shares are held by insiders. Comparatively, 23.6% of Harmony Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media favor BPMC or HRMY? In the previous week, Harmony Biosciences had 7 more articles in the media than Blueprint Medicines. MarketBeat recorded 8 mentions for Harmony Biosciences and 1 mentions for Blueprint Medicines. Harmony Biosciences' average media sentiment score of 1.59 beat Blueprint Medicines' score of 0.00 indicating that Harmony Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Blueprint Medicines 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Harmony Biosciences 6 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more risk & volatility, BPMC or HRMY? Blueprint Medicines has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Do analysts prefer BPMC or HRMY? Blueprint Medicines currently has a consensus price target of $130.00, indicating a potential upside of 0.42%. Harmony Biosciences has a consensus price target of $51.00, indicating a potential upside of 48.26%. Given Harmony Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Harmony Biosciences is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blueprint Medicines 0 Sell rating(s) 16 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11Harmony Biosciences 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is BPMC or HRMY more profitable? Harmony Biosciences has a net margin of 20.53% compared to Blueprint Medicines' net margin of -27.70%. Harmony Biosciences' return on equity of 24.32% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Blueprint Medicines-27.70% -64.60% -17.22% Harmony Biosciences 20.53%24.32%15.92% Which has better valuation & earnings, BPMC or HRMY? Harmony Biosciences has higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlueprint Medicines$562.12M14.87-$67.09M-$2.47-52.41Harmony Biosciences$714.73M2.76$145.49M$2.6213.13 SummaryHarmony Biosciences beats Blueprint Medicines on 15 of the 17 factors compared between the two stocks. Get Harmony Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for HRMY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HRMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HRMY vs. The Competition Export to ExcelMetricHarmony BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.02B$3.00B$5.49B$9.52BDividend YieldN/A2.43%4.73%4.09%P/E Ratio13.1317.6228.7823.81Price / Sales2.76179.21372.2066.04Price / Cash11.9441.9535.4557.96Price / Book2.988.508.275.54Net Income$145.49M-$55.06M$3.25B$259.28M7 Day Performance-8.32%-3.99%-3.70%-4.64%1 Month Performance7.13%9.58%4.34%4.41%1 Year Performance6.17%6.70%25.90%17.95% Harmony Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HRMYHarmony Biosciences4.7824 of 5 stars$34.40-2.2%$51.00+48.3%+5.1%$2.02B$714.73M13.13200Positive NewsUpcoming EarningsBPMCBlueprint Medicines0.7266 of 5 stars$129.46flat$128.25-0.9%N/A$8.36B$562.12M-52.41640Upcoming EarningsLEGNLegend Biotech3.5917 of 5 stars$41.51-4.3%$73.33+76.7%-29.5%$7.97B$627.24M0.002,609Positive NewsROIVRoivant Sciences2.072 of 5 stars$11.35-1.7%$16.50+45.4%+6.5%$7.85B$29.05M0.00860Positive NewsUpcoming EarningsRGCRegencell Bioscience0.0502 of 5 stars$13.80-8.3%N/AN/A$7.44BN/A0.0010Positive NewsELANElanco Animal Health3.8177 of 5 stars$14.59-2.2%$16.17+10.8%+5.9%$7.41B$4.44B15.879,000Positive NewsUpcoming EarningsRVMDRevolution Medicines4.467 of 5 stars$37.26-1.7%$68.91+84.9%-19.1%$7.06B$11.58M0.00250News CoveragePositive NewsUpcoming EarningsGRFSGrifols3.116 of 5 stars$10.09-0.1%$10.30+2.1%+41.1%$6.94B$7.81B0.0023,822Dividend AnnouncementTGTXTG Therapeutics4.0794 of 5 stars$35.99-2.5%$43.80+21.7%+85.0%$5.86B$329M153.75290Positive NewsUpcoming EarningsNUVLNuvalent3.2323 of 5 stars$81.94+0.7%$119.60+46.0%+2.0%$5.85BN/A0.0040Positive NewsCRSPCRISPR Therapeutics2.8206 of 5 stars$63.75-1.6%$71.31+11.9%+2.3%$5.59B$37.31M0.00460Upcoming EarningsAnalyst RevisionGap Down Related Companies and Tools Related Companies Blueprint Medicines Alternatives Legend Biotech Alternatives Roivant Sciences Alternatives Regencell Bioscience Alternatives Elanco Animal Health Alternatives Revolution Medicines Alternatives Grifols Alternatives TG Therapeutics Alternatives Nuvalent Alternatives CRISPR Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HRMY) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harmony Biosciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harmony Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
